The Brain on Estrogen: Rethinking Appetite Through Neurohormonal Insight
For decades, estrogen has been understood primarily as a reproductive hormone—cyclic, ovarian, and deeply entwined with fertility. But in recent ...
When Health Records Become Hostage: The Rise of Espionage in Healthcare Data Breaches
In an era where health data has become as valuable as financial records—and in some cases, even more exploitable—the latest ...
Restructuring Health: The Quiet Dismantling of America’s Public Health Workforce
In an announcement met with both bureaucratic precision and public confusion, the U.S. Department of Health and Human Services (HHS) ...
Contagion by Choice: The Measles Outbreak Testing Public Health and Policy in the American Southwest
In early March 2025, a case of measles in a Dallas-area elementary school seemed like a statistical anomaly—a rare but ...
The Midlife Market: How Menopause Care Finally Went Mainstream
In the quiet margins of healthcare, menopause has long stood as a gaping omission. A ubiquitous biological transition that affects ...
Rethinking the Gut Health Craze: The Science Behind Microbiome Research and Probiotic Skepticism
In recent years, the gut microbiome has emerged as a glamorous frontier in health and wellness, touted as a panacea ...
Medicare’s Bold Step: The First 10 Drug Price Negotiations and Their Ripple Effects
In a historic policy shift, Medicare has begun direct negotiations on the prices of 10 widely used prescription drugs, marking ...
The Rising Tide of Healthcare Worker Strikes: A Reflection of Economic and Political Tensions
In recent months, a surge in healthcare worker strikes has emerged across the United States, highlighting deep-seated economic and political ...
Donanemab’s FDA Panel Approval: A Breakthrough Moment for Alzheimer’s—and a Cautionary Tale for Biotech
In a highly anticipated decision, an advisory panel to the U.S. Food and Drug Administration (FDA) voted overwhelmingly to support ...
NIH Long COVID Findings: Progress, Frustration, and the Unfinished Puzzle of Post-Viral Illness
Nearly four years into the COVID-19 pandemic, Long COVID remains one of its most haunting legacies—a shadow epidemic affecting millions ...
Second Opinion, First Defendant: How AI Is Redrawing the Legal Map in Radiology
Who gets sued when the algorithm is wrong? That question, once theoretical, is now central to a field undergoing radical ...
RSV Vaccines for the Youngest and the Oldest: A Public Health Milestone—and a Public Trust Test
After decades of research and anticipation, the medical community is celebrating a significant breakthrough: the arrival of respiratory syncytial virus ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more